Policy & access
FDA has announced a public meeting to gather comments on the Commissioner’s National Priority Voucher pilot program, aimed at enhancing drug development for rare diseases. This initiative reflects the agency's commitment to continuous quality improvement in the regulatory process.
As part of the U.S. Food and Drug Administration’s continuous quality improvement efforts, the agency today published a Federal Register Notice seeking public comment on the Commissioner’s National Priority Voucher pilot program.
Original title: “FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program”